氯氮平治疗精神分裂症阴性阳性症状的临床研究

氯氮平治疗精神分裂症阴性阳性症状的临床研究杨甫德，吉中孚，刘华清抗精神病药对精神分裂症的阳性和阴性症状的疗效尚有不同意见，一般认为对阳性症状效果较好，见效较快，对阴性症状则较差较慢；也有人认为两者变化呈正相关的关系。氯氮平对阴性阳性症状的作用，也有不...     

精神分裂症阴性症状的药物治疗

精神分裂症阴性症状的药物治疗苏州市广济医院（２１５００８）吕永良，钱连华７０年代末以来，Ｃｒｏｗ、Ａｎｄｒｅａｓｏｎ等提出精神分裂症有两种不同类型，一种是产生阳性症状（ＰＳＳ），其生物学基础是多巴胺功能不进；另一种是产生阴性症状（ＮＳＳ），其病理基础...     

精神分裂症阴性症状的治疗及预后

精神分裂症属精神科疾病疑难重症之一,而其阴性症状可属其难中之难。尽管如此,仍有许多不畏艰辛的人们从夹缝中寻求有效的治疗途径。预后与治疗效果是紧密联系在一起的,有了好的治疗效果预后自然乐观了。现就这一问题给以阐述。     

精神分裂症的阴性症状

精神分裂症的阴性症状北京回龙观医院（１０００８５）杨甫德，吉中孚，刘华清本文拟对精神分裂症的阴性症状作一概述，以期引起精神医学界同仁对阴性症状给予更多的关注。１阴性症状的生物学基础在７０年代未，Ｃｈｏｕｉｎａｒｄ就对阴性症状进行了生物学的解释，认为脑...     

精神分裂症阴性症状的药物治疗进展

阴性症状作为精神分裂症核心症状之一,目前仍缺乏有效的靶向性治疗,是影响预后的主要不利因素。根据不同的生物学机制,当前临床研究主要关注抗精神病药单用或其联合抗抑郁药、抗焦虑药、谷氨酸化合物及抗炎药等对阴性症状的疗效,本文通过对精神分裂症阴性症状常用的药物疗法进行归纳总结,分析不同疗法的效果,以期为临床治疗阴性症状提供参考。     

对阴性症状和阳性症状认识的评价（四）：四,精神分裂症症状流变学

对阴性症状和阳性症状认识的评价（四）四、精神分裂症症状流变学金卫东，王高华对精神分裂症的多巴胺假说提出疑问之后，继而转向阴性症状等诸方面的研究，充分显示了阴性症状在生物学、遗传学、神经心理学等方面与阳性症状不同，甚至截然相反，由此引起了人们对这两组症...     

帕罗西汀治疗精神分裂症阴性症状

我们以单用抗精神病药和抗精神病药合用帕罗西汀治疗以阴性症状为主的精神分裂症,进行临床对照,报告如下。     

精神分裂症阴性症状治疗的研究进展

本文通过查阅有关精神分裂症阴性症状治疗的近期相关文献,对药物治疗和非药物治疗的研究情况予以综述.     

Treatment of schizophrenia negative symptoms: future prospects

New findings from neuroscience, genetics, and experimental psychology have emerged that provide alternative explanations of many negative symptoms. We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments.     

Treatment of negative symptoms in schizophrenia with neuroleptics

Different concepts of negative symptoms in schizophrenia are reviewed. The beneficial effects of neuroleptics are discussed. The results of a pharmacokinetic and pharmacodynamic study with Amisulpride in healthy volunteers are reported. Preliminary findings of a study with Amisulpride in schizophrenic patients with predominately negative symptoms are presented. The utility of various rating scales for documenting the clinical state of these patients during therapy, and correlations of negative symptoms with psychometric and psychophysiological data are discussed. Finally, therapeutic consequences suggested by different hypothesized etiological factors causing negative symptoms are considered.     

利培酮合并舍曲林治疗精神分裂症阴性症状的研究

目的探讨舍曲林合并利培酮治疗精神分裂症阴性症状的疗效及安全性。方法将86例以阴性症状为主的住院精神分裂症患者随机分为研究组(舍曲林 利培酮)和对照组(利培酮 安慰剂)。在治疗前及治疗后4、8、12周,用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)评定疗效和安全性。结果治疗后8、12周,两组PANSS总分、阴性因子分比较差异有统计学意义(P<0.05)。研究组阴性因子各项症状评分低于对照组,差异有统计学意义(P<0.05或P<0.01)。而两组TESS评定无统计学意义(P>0.05)。结论舍曲林合并利培酮治疗精神分裂症阴性症状安全有效,副作用少。     

Management of negative symptoms of schizophrenia

Persistent negative symptoms are a major cause of chronic disability in schizophrenia. The primary management approach for negative symptoms is use of atypical antipsychotics. Among atypical antipsychotics, clozapine produces the most robust reductions in negative symptoms. Lesser degrees of reduction are observed with risperidone and olanzapine. However, it remains unclear whether these agents treat core negative symptoms of schizophrenia, or simply induce less secondary psychopathology. A second approach for treatment of persistent negative symptoms is the use of N-methyl-D-aspartate (NMDA) receptor-stimulating agents, such as glycine, D-serine, or D-cycloserine. Significant benefit of these agents has been observed in combination with both conventional and newer atypical antipsychotics. Whether or not these agents are effective in combination with clozapine remains an open question, and large scale multicenter clinical trials are ongoing.     

Management of negative symptoms of schizophrenia

Persistent negative symptoms are a major cause of chronic disability in schizophrenia. The primary management approach for negative symptoms is use of atypical antipsychotics. Among atypical antipsychotics, clozapine produces the most robust reductions in negative symptoms. Lesser degrees of reduction are observed with risperidone and olanzapine. However, it remains unclear whether these agents treat core negative symptoms of schizophrenia, or simply induce less secondary psychopathology. A second approach for treatment of persistent negative symptoms is the use of N-methyl-D-aspartate (NMDA) receptor-stimulating agents, such as glycine, D-serine, or D-cycloserine. Significant benefit of these agents has been observed in combination with both conventional and newer atypical antipsychotics. Whether or not these agents are effective in combination with clozapine remains an open question, and large scale multicenter clinical trials are ongoing.     

Positive and negative symptoms in schizophrenia

Negative and positive symptoms were determined for 46 drug-free patients who met Research Diagnostic Criteria (RDC) and/or Feighner criteria for schizophrenia. A modified version of the Scale for the Assessment of Negative Symptoms (SANS) was completed for each patient based on items from the Schedule for Affective Disorders and Schizophrenia (SADS) and other scales. Positive symptoms were scored from the SADS as well as from the following four diagnostic systems: RDC, Schneider's first-rank symptoms, the 12-point Flexible system, and Langfeldt's criteria for poor prognosis schizophrenia. For all patients, there was no correlation of negative symptoms and positive symptoms defined by any diagnostic system. Within the paranoid and undifferentiated subtypes, there was a positive correlation of positive and negative symptoms. Patients moving from stable to exacerbated states had an increase in both positive and negative symptoms, and patients with a poor history of treatment response had both more positive and more negative symptoms than responsive patients in a stable state. These results do not support the view that subgroups of patients have predominantly either negative or positive symptoms.     

Treatment of negative symptoms in schizophrenia: a challenge for clinical research

European Archives of Psychiatry and Clinical Neuroscience -     

Treatment of negative symptoms

The rational treatment of the negative symptoms of schizophrenia requires a careful differentiation of those secondary to a range of other factors and those that constitute enduring primary or deficit symptoms. Secondary negative symptoms are usually responsive to treatment of the underlying cause. In contrast, there is no intervention currently available with established efficacy in treating deficit symptoms. These distinctions serve to reduce the heterogeneity of negative symptoms. A discussion of the diagnosis and treatment of the various forms of secondary negative symptoms is followed by suggestions for future research in the treatment of deficit symptoms.